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 The commercialization of medical products at the university level is a multilayered and 
challenging process. One barrier to commercialization is the difficulty of meeting Food and Drug 
Administration (FDA) regulatory requirements. Regulations and standards are undoubtedly 
necessary to maintain the highest product safety levels, but it creates many obstacles.  This paper 
will analyze how researchers involved with early-stage medical device innovation in a university 
setting deal with FDA compliance issues and the implications of this engagement for innovation. 
I conducted an exploratory case study of ten medical product development projects at the 
Rochester Institute of Technology (RIT). Overall, I found that FDA approval pathways were 
challenging for project participants to navigate without proper resources; approximately half of 
the projects indicated a lack of confidence in their knowledge of and/or progress towards 
meeting FDA requirements based on the resources available. I offer several suggestions 
regarding how RIT and other universities can reduce barriers to innovation caused by FDA 








Chapter I: Introduction 
 
Introduction  
 Universities often foster the creation of medical devices through their support of research 
and new ideas. Research centers and labs can support innovation, test theories, and devices 
without the market pressures that medical device companies experience. Medical technology is 
advancing quickly, as seen in the ever-growing healthcare market. Luckily, medical research in 
universities can pursue ideas and theories that may have a low chance of success. Their ability to 
take risks without the possibility of failure has allowed groundbreaking discoveries. When a 
medical product is created or discovered that the researcher believes is worth pursuing 
commercially, it moves forward for further testing, approval, and commercialization. Thus, it is 
essential for any life-changing medical product created in the university setting to have adequate 
commercialization compliance support. Without the proper permission, documentation, and 
resources, a life-saving technology may not reach the people that need it.  
A medical device falls into a category of products that is overseen by the government. 
The department known for oversight within the government is the Food and Drug Administration 
(FDA). They are responsible for the approval processes that allow medical products to be on the 
market. Once a product is developed enough to be considered for FDA approval, the creator or 
university decides whether to pursue it.  The decision to pursue commercialization and approval 
may seem like an easy decision; however, literature and research shows that the approval process 
at this level can be challenging, expensive, and hard to navigate (Gulbranson & Audretsch, 
2008).  
Commercializing a medical device requires compliance with FDA regulations, which is 
challenging to obtain and requires knowledge of the processes involved, as well as financial 
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resources. Most recommendations for improvement to universities to help with this process 
include changes to organizational structure or funding. As will be discussed in the literature 
review, few papers offer any specific advice relating to regulatory compliance or any case 
studies of successful models for overcoming university innovators’ regulatory barriers.  
Thus, the goal of this thesis is to take a more in-depth look at how FDA regulations 
impact early-stage medical device innovation projects at the university level. To do this, I 
performed exploratory case studies of medical products in different stages of development at one 
university. The interview questions targeted multiple aspects of their experience, such as 
regulatory and compliance resources, barriers to innovation, and the university’s impact on 
project success. After presenting my findings and analysis, I discuss the implications of this 

















Chapter II: Background of FDA and Definitions 
 
Medical device innovation is a critical component in the growing field of medicine and 
comprehensive care. Under the guidance of the Food and Drug Administration (FDA), the 
definition of a medical device is (O. O. Affairs, 2018) 
“an instrument, apparatus, implement, machine, contrivance, implant, in vitro 
reagent, or other similar or related article, including a component part or 
accessory which is: recognized in the official National Formulary, or the United 
States Pharmacopoeia, or any supplement to them, intended for use in the 
diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or 
prevention of disease, in man or other animals, or intended to affect the structure 
or any function of the body of man or other animals, and which does not achieve 
its primary intended purposes through chemical action within or on the body of 
man or other animals and which is not dependent upon being metabolized for the 
achievement of any of its primary intended purposes.” 
 
Under this definition, there are many different types of medical devices, with varying 
degrees of intrusiveness or potential for harm. For example, a tongue depressor and a pacemaker 
are both considered medical devices, although one is less dangerous than the other. The variance 
in danger calls for a different level of regulation. 
 Device classifications are a way to categorize medical devices based on their risks and 
the regulatory controls necessary to provide a reasonable assurance of safety and effectiveness. 
(Center for Devices and Radiological Health. (2017)).  Figure 1 shows the differences between 
Class I, II, and III devices. The examples of products range in simplicity and class based on the 







Figure 1: Types of device classifications and the differences between them (Geete, 2016).  
 
Below are definitions of several terms that I use in this thesis. These terms explain the 
FDA, different approval pathways, and the difference between a medical device and equipment.  
Definitions       
510(k)- is a premarket submission made to the FDA to demonstrate that the device to be 
marketed is as safe and effective, that is, substantially equivalent, to a legally marketed device 
(section 513(i)(1)(A) FD&C Act) that is not subject to premarket approval. 
 (510(k) Premarket Notification, n.d.) 
 
Equipment: Medical devices requiring calibration, maintenance, repair, user training, and 
decommissioning – activities usually managed by clinical engineers. Medical equipment is used 
for the specific purposes of diagnosis and treatment of disease or rehabilitation following disease 
or injury; it can be used either alone or in combination with any accessory, consumable or other 
piece of medical equipment. Medical equipment excludes implantable, disposable, or single-use 
medical devices. (Medical Device – Full Definition, 2018)  
 
FDA (Food and Drug Administration)- The Food and Drug Administration is responsible for 
protecting the public health by ensuring the safety, efficacy, and security of human and 
veterinary drugs, biological products, and medical devices; and by ensuring the safety of our 




Medical device: article, instrument, apparatus, or machine that is used in the prevention, 
diagnosis, or treatment of illness or disease, or for detecting, measuring, restoring, correcting, or 
modifying the structure or function of the body for some health purpose. Typically, the purpose 
of a medical device is not achieved by pharmacological, immunological, or metabolic means. 
(Medical Device – Full Definition, 2018) 
 
Predicate Device-A predicate device is a medical device that may be legally marketed in the 
U.S. and used as a point of comparison for new medical devices seeking approval through 
FDA’s 510(K) premarket clearance pathway. The new device must be proven to be substantially 
equivalent in safety and efficacy to the predicate device in order to receive clearance. 
(Predicate Device: Greenlight Guru, (n.d.)). 
 
Pre-market Approval - is the FDA process of scientific and regulatory review to evaluate the 
safety and effectiveness of Class III medical devices. Class III devices are those that support or 
sustain human life, are of substantial importance in preventing impairment of human health, or 
which present a potential, unreasonable risk of illness or injury.  
(Premarket Approval (PMA), 2020) 
 
Translational Research- the process of applying knowledge from basic biology and clinical 
trials to techniques and tools that address critical medical needs.  
















Chapter III: Literature Review  
 
The Food & Drug Administration (FDA) recently published a document that states the 
main objective of regulatory entities is “helping to ensure that innovation in product 
development continues, so that patients can get groundbreaking medical products while at the 
same time ensuring patient safety and that harmful medical devices do not reach the market 
(O.O. Commissioner, 2018).”  However, a Harvard Business Review article (Minguillo & 
Thelwall, 2014) describe current innovation in healthcare as “unsuccessful.”  They discuss six 
forces that affect the success or failure of innovation: players, funding, policy, technology, 
customers, and accountability. It may not be that all of these are equally important in a university 
setting. In the following sections, I will thus focus on reviewing the literature on regulatory 
compliance and commercialization in universities in particular.  
 
Commercialization in Universities 
The costs associated with regulatory compliance are two of the most considerable 
burdens on innovation. As stated by Herzlinger (2006), “One problem is the long investment 
time needed for new drugs or therapies that require FDA approval. While venture capitalists 
backing an IT start-up may be able to get their money out in two to three years, investors in a 
biotech firm have to wait ten years even to find out whether a product will be approved for use.” 
Innovation in universities is similarly challenged, and the difficulty of bringing a product to 
market is a risk that must be weighed. Unlike private firms, however, a university's number one 
goal is to research and explore new ideas, which may not include commercialization. If they are 
using resources to prepare something for commercialization, it must show promise; even if there 
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is a promise of success, however, the risk of failure may prevent the pursuit of 
commercialization.  
Despite the risks of commercialization, there has been a steady increase in the desire for 
commercial outcomes from university research since the early 2000s (Ambos et al., 2008). While 
this increased push for the commercialization of new technology may bring increased risks, a 
healthy support system at a university can reduce this risk and help universities claim the 
benefits of commercialization, such as income and increased reputation. 
The promise of income and increased reputation has driven support for more 
commercialization of technical innovation at universities (Ambos et al., 2008). Policymakers 
also support this trend for more innovation because it increases competitiveness in the market. 
They often have specific initiatives and incentives to encourage more universities to participate 
in medical device innovation (Ambos et al., 2008). However, while it is mutually beneficial to 
commercialize university research, it is not always easy. One issue is that different stakeholders 
involved in innovation may have different motives. For example, universities have education and 
research as the primary motivation, while players in the market have patient care, 
competitiveness, and profit as their motivations (Marantz et al., 2010).  In addition, poor 
knowledge management, cultural differences, and bureaucratic struggles can hamper 
commercialization efforts (Siegel et al., 2003). Pober et al. (2001) argue that contributing to the 
low rate of commercialization, or translation, from universities is the fact that process can vary 
from case to case and, as a result, is not straightforward or consistent. Also, the authors recognize 
the need for continued research and collaboration, even following the commercialization of 




There is some evidence that universities can overcome these challenges and see success 
in commercialization. There are many reasons for this, but most experts agree that it takes 
additional structures at the university level to achieve smooth commercialization. An example of 
this is the University of Michigan. They have attempted to create a model for this through their 
partnership with the Wallace H. Coulter Foundation (Pienta, 2010). This partnership resulted in a 
center that helps build structures and change the university culture to better support collaboration 
between the university faculty and professionals in the medical field. As explained on the 
Coulter Translational Research Partnership Program website, the center is described as follows 
(About the Program, 2016): 
The U-M Coulter Translational Research Partnership Program is a commercialization 
fund that seeks to accelerate the development of university technologies into new 
products to improve health care. The program funds 5-7 projects per year for an average 
of over $100,000 each. Each project must involve a collaboration between UM faculty 
from any college of engineering department and a practicing clinician from a clinical 
department. Each project aims to generate a new medical device, surgical tool, diagnostic 
assay or other biomedical tool and is mentored by a team of industry experts to guide 
projects to the point of start-up, partnering with industry, and/or follow-on funding. 
 
Minguillo and Thelwall (2014) found that these new infrastructures appear to have the 
most success in having positive interactions between universities and the market. Another type of 
enabling structure is a proof-of-concept center. University researchers struggle to obtain funding 
during the early stages, and a proof-of-concept center bridges that gap by providing researchers 
with appropriate funding (Gulbranson & Audretsch, 2008). With that said, creating these new 
structures takes a certain amount of time, resources, and effort that many universities simply 





Regulatory Compliance  
The overall success of the product can not be achieved without compliance with the FDA 
and other regulatory bodies. Compliance with the FDA is challenging and requires both 
knowledge of the regulatory process and a high amount of resources. This leads to more 
commercialization success at the large company level than the university level (Schwartz & 
Macomber, 2017). As just discussed, most recommendations of improvement to universities 
include changes to organizational structure and/or funding. Noticeably absent from the literature, 
however, was any mention of specific recommendations relating to assistance with regulations or 
the compliance of devices.  
Medical devices vary significantly in their use, risk, complexity, and other characteristics. 
Understanding how individuals at universities handle the burden of compliance for such a range 
of products should be researched and understood.  It was surprisingly difficult to find 
information detailing success case studies or a model for overcoming regulatory body barriers 
for university innovators. Throughout the literature review, there were examples of successful 
medical innovations, yet not nearly enough recommendations for becoming successful in the 
stages where compliance is necessary.  
Thus, while the literature discusses how universities have found success in medical 
device innovative efforts through culture change, increased funding, and new structures, it is 
unclear how these universities have achieved regulatory compliance success. It is evident that a 
university must show a genuine interest in growing the success of innovation in order to grow 
their program. However, what they need to do to provide support for regulatory compliance 
remains unclear. The potential of university medical research could be endless, but the lack of 
understanding in compliance processes is holding back many institutions. Therefore, the gap of 
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information found in this literature review shows that universities need a greater understanding 
of the regulatory barriers to commercializing their medical device innovations.  
 
Research Question: 
The literature review addresses commercialization in universities and regulatory 
compliance. As shown in the literature review, commercialization is an increasingly common 
goal for university-based medical device innovation. The literature review shows a large gap in 
our knowledge of how regulatory compliance impacts medical device innovation at the 
university level and how universities can help with respect to compliance issues.  Thus, in this 
thesis, I ask:  How does FDA regulation impact early-stage medical device innovation projects 
at the university level? In particular, three specific sub-questions are looked at:  
1. What sources of information did the project use to learn about compliance 
standards for FDA regulations? 
2. What barriers to innovation have the project owners faced with regard to 
regulatory compliance and how did they overcome these barriers? 
3. How do the information sources and barriers impact the product design and 








Chapter IV: Methodology 
       
Data Collection  
Access was a deciding factor in choosing to focus on the RIT population’s medical 
products and research. It would have been challenging to contact other universities to access 
their staff, students, and research while keeping anonymity. Remaining within RIT gave a more 
focused study and decreased the possibility of delays or issues. Also, RIT is an exciting 
institution to analyze because it is very active in medical innovation. Still, it does not have an 
associated medical school to conduct trials at or implement the innovation.  
Snowball sampling was the method used to recruit possible products (Johnson, 2014). I 
reached out to past and present department heads in the Kate Gleason School of Engineering to 
create a list of potential research contacts. The potential products needed to meet specific 
requirements to participate in the study. The products needed to be created on the Rochester 
Institute of Technology campus, be classified as a medical product and be recognized by RIT as 
a university project. The products were chosen to represent a wide range of innovation types. 
Once the devices were selected, the contacts received an email asking for participation in the 
study; all contacts responded and agreed to participate.  
After connecting with all contacts, selecting ten medical device projects ranging from 
beginning stages to commercialization took place. All products and subjects remain confidential 
to keep any intellectual property concerns to a minimum. Due to the COVID-19 lockdown and 
quarantine, the interviews could not be held in person and instead were on ZOOM during the 
Spring and Summer of 2020. All of the meetings were recorded and placed in a private drive 
with the interviewees’ consent. The meetings were transcribed word by word to allow for direct 
quote use.  
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After gathering information about each project, I created tables to assign a coded number 
and compare their basic details such as device class, owner, and function. Doing so kept the 
anonymity of the products while also keeping the product list consistent. After the general 
product details were analyzed, I created tables that contained more specific information to 
compare the resources used for compliance and regulatory data.  The resources varied based on 
the type of product. The transcripts were analyzed to pull out direct quotes of the barriers faced 
by project owners. The most prevalent barriers described in the transcripts were examined and 
further analyzed. Lastly, the impact of university policy and regulation was analyzed for the 
specific project types and explained further. 
Due to the patterns seen across the projects, I decided to split the data and tables apart 
into three sections. The three sections are labeled Sponsored Projects, Research Projects, and 
Individual Projects, to be defined later. After dividing the sections and splitting the tables, I also 
created three subheadings for each section. The three subheadings for each product are labeled as 








Chapter IV: Analysis of Data 
Overview of Projects 
Table 1 shows the ten products chosen for the thesis. For anonymity, the products 
received a corresponding number used throughout the analysis and a basic description. The basic 
description is an indication of the complexity and risk of the product. For example, an 
implantable device is riskier than a modeling device. The risks described in the class column 
correlate with the basic description and can aid in understanding the product. The goal of the 
project states the end result the owner intends to reach. Commercialization means the project was 
intended to be commercialized from conception. Research with intent to market means the 
owner’s primary goal is basic research but is willing to commercialize with a successful product. 
Lastly, basic research means there is no intent to commercialize the product. 
Table 1:  Description of the type of product, product FDA class, and the goal of the 
product project. See definition sections for explanation of the categories. 
Product Type of Product Class Basic Description Goal of Project 
1 Device I External health monitoring system Commercialization 
2 Device III Implantable device Research with intent to market 
3 Equipment I Assistive equipment Commercialization 
4 Equipment I Modeling device Basic research 
5 Device I Assistive equipment Commercialization 
6 Equipment I Biological prototyping device  Commercialization 
7 Device I or II 
Investigative Autonomical Tool 
Used During Physical Exams Commercialization 
8 Device III 
Technological Advancement for 
Assistive Devices  Basic research 
9 Device III Life-Sustaining Internal Device Research with intent to market 




At least half of the products are Class I products, the lowest risk class, while three of the 
products were Class III. I also classified the projects as being focused on either devices or 
equipment to give the reader a better understanding of their function. A device is used in the 
prevention, diagnosis, or treatment of illness or disease or for detecting, measuring, restoring, 
correcting, or modifying the structure or function of the body for some health purpose. In 
contrast, equipment is used for activities usually managed by clinical engineers. Medical 
equipment is used for the specific purposes of diagnosis and treatment of disease or rehabilitation 
following disease or injury (Medical Device – Full Definition, 2018). Out of the ten products, 
seven are classified as devices, while the other three are equipment.   
As seen in Table 2, the product’s origin is an indicator of the type of support it has from 
the university. A research product originates in a research lab. The university, along with 
external research grants, financially supports the project and RIT staff are the project leaders. 
Sponsored Projects originate from clients internal or external to the university and are run by 
students; while the university does not fund them, students can use available resources at RIT. 
Participants in Research and Sponsored Projects would acknowledge the role the university 
played in the case of a successful product. Lastly, Individual Projects are those recognized by 
RIT but do not use RIT funds and would not recognize RIT as a stakeholder of the project. The 
findings in Table 1 and 2 show that all Class I, or the lowest risk projects, fell under Sponsored 
Projects and were run by students, while three out of the four Research Projects were Class III. 









Table 2: Range of products chosen based on origin, collaborator, and project owner.  
Product Origin Collaborator Project Owner 
1 Research Project Company  Staff 
2 Research Project Company  Staff 
3 Sponsored Project N/A Student 
4 Sponsored Project N/A Student 
5 Sponsored Project N/A Student 
6 Sponsored Project N/A Student 
7 Sponsored Project N/A Student 
8 Research Project N/A Staff 
9 Research Project Company Staff 
10 Individual Project N/A Student 
 
Research Projects 
As stated earlier, the research products exist in a research lab and run by RIT staff. All 
products in this section are devices that are used directly by medical staff (i.e., pacemakers, 
artificial hips) rather than equipment that is often managed by engineers (i.e., patient monitors). 
This section will look at the resources for compliance, barriers experienced by project owners, 
and the impact of these resources and barriers on ultimate product design and project success.  
 
Information Resources 
 The design process for a typical medical product begins with an idea and ends with 
commercialization. To create a successful medical product, each stage of innovation relies on 
knowledge gained from various resources. Without knowing the proper design and safety 
requirements, a medical device can not reach the market and be successful. Based on its device 
class, each product needs to meet different design and testing criteria for the chosen FDA 
pathway. The impact of good or bad information sources can affect the outcome of the ability of 
a product to comply with regulatory requirements, as well as choices in the design itself. Low-
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quality information is more likely to harm the product, while a high-quality source will help the 
product advance through the innovation process. Common compliance information needs include 
device classifications, approval pathways, design criteria, necessary documentation, and testing 
requirements documents.  
Table 3 details the resources used to gather information on regulatory standards in the 
Research Projects.  Six primary sources provided the information on FDA guidelines for 
products. These sources are design standards (such as ISO, IEEE), expert consults, other 
established companies, customers, a general internet search, and looking at existing technology.  
A consistent theme in the interviews was how information about regulatory requirements for a 
specific product was difficult to come by.  Across the ten devices, most researchers obtained 
their knowledge through different sources. 
  
 
Table 3: Resources used to gather the FDA process and design criteria for research products. 
 




Consult Company Customer Internet 
Existing 
Technology 
1 RIT/ Company X X X    
2 NIH/RIT/ Company  X X X   
8 Company/ NIH/RIT   X   X 
9 RIT  X   X X 
 
 
All four of the Research Projects, headed by RIT staff, were able to connect with experts 
or have a relationship with companies. A range of other resources was used as well, although not 
the same extent as experts and companies. Having information sources backed by experienced 
companies and institutions outside of RIT provided an adequate level of confidence in the quality 
of information and expertise. The experts seem to be available through RIT connections, as well 
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as external connections gained through the personal researcher’s network developed over their 
career.  The experts used by the researchers are not shared across others in the university. There 
is typically a high degree of confidence about the quality of data through expert consultants and 
companies with prior experience. Thus, these projects have access to reliable information on 
FDA compliance. 
Product 1 is a low-risk device, as shown in Table 1. The owner of the device believes the 
device has the potential to be successful and is pushing the product to market. The owner of the 
project started a company to support any of the product needs. This company is specifically 
dedicated to the success and commercialization of the product. The interviewee stated that “the 
company is taking it through the FDA. That is expensive to do, and there is expertise that is 
required to do it. The company has an FDA consultant who understands how to go about doing 
those filings with the FDA.”  
 Translational research, as defined previously, is specifically designed to improve health 
outcomes. It uses an integrated team of experts who are focused on translating useful information 
from laboratories to doctors’ offices and hospitals and is a “bench to bedside” bridge (“What is 
Translational Research?,” 2017). The translational pathway of research to commercialization is 
not common at RIT; with limited past translated products to use as a model, innovation at RIT is 
challenging. The interviewee believes going through the FDA approval process is extremely 
uncommon on campus. The interviews indicated that this lack of experience could harm the 
translational process. The limited knowledge of the university showcases the lack of resources 
available to entrepreneurs, engineers, and collaborators to commercialize innovation.  Luckily, 
the company created to assist the product has hired experts, and the product will have the 
resources needed to move forward. 
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Product 2, a Class III device, is still being used on animals, which limits the involvement 
of the FDA. When the researcher plans to move forward, their path will include collaboration 
with a larger company to assist in human testing and gaining FDA approval. The cost and time 
associated with testing a Class III device can be overwhelming for a university with limited 
experience.  The interviewee believed that “most academics do not have any experience with that 
[FDA testing and approval].  It is very different from the majority of what we do for our research 
and how we write proposals.  Usually, people would partner with companies.” Based on the 
researcher's experience, collaboration with a larger company seems to be the most efficient way 
for a Class III technology to be translated. 
Product 8’s project leaders have possible plans to commercialize their Class II product. 
The progress of the product has not yet reached a point that requires the attention of the FDA for 
compliance. However, early consideration of FDA requirements could help avoid problems later 
on. Understanding different approval pathways and compliance standards could lead to changes 
that pay off later. The researcher already has plans to work with a multinational company for 
further testing and translation of the product once the product is ready for an FDA pathway. This 
company has experience with similar products and believes this is the best way to advance. 
Product 9, a Class III device, is not going to be commercialized. Their project was a 
response to the COVID-19 pandemic, and their efforts proved to be fruitless as they did not have 
the resources to continue. Before the COVID-19 pandemic led to a partial shut down of 
university activities, the project members explored the FDA approval process through self-
research and outside collaborators. The interviewee explained, “the problems that we were 
tackling there were not any regulations that would have hindered us, and if there were any 
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regulations, we were letting our partners make those decisions.” The resources used for approval 
of this project would not have come from the university but outside consultants.  
 In sum, three out of the four Research Projects planned to use the help of companies, and 
the other used expert consultation through external collaborations. The Research Projects 
gathered information from additional sources, such as companies and consultants. Collaboration 
with companies has extreme advantages, such as knowledge, staff, and funding. Working with 
the company gives a researcher the freedom to continue working on their work at the university, 
yet both parties can benefit.  Based on the research, there are few currently known disadvantages 
for company collaboration. For university innovators with little experience, a company can be 
the difference between success or failure.  
 
Experienced Barriers 
Lack of Knowledge 
At RIT, researchers are responsible for many of the products that may result in a 
commercial product, but they can also experience barriers that stunt their possible successes. 
There are many things about regulation and compliance that researchers don’t know and can not 
learn at the university. Luckily, the researchers in this study tended to have enough resources 
outside of the university to overcome this barrier.  
 One of the specific barriers experienced by the researchers was a lack of knowledge of 
documentation procedures. The FDA requires not only documentation for the final product, but 
also the process of developing the product. This can include design, test results, and other 
process steps. However, there is little to no standard documentation process to assist researchers 
in commercialization. A researcher stated, 
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“We don’t have documented procedures that define the way we do product development.  
We don’t do a good job with documenting the design.  We don’t do a good job with 
documenting the way that we produce it.  We don’t have procedures for the way that you 
make them, and we don’t have procedures for everything you test in a quality system 
where we take all of that data, and it’s documented for every device.  What that means is, 
if I produce the devices out of the university and we get all these great results from this 
study, which is a five-year study, I can’t actually use it to submit to the FDA. We have to 
do it again.  It still has value, because it can show with technology like this, you can 
reduce hospitalization rates.  You just can’t use that data to file with the FDA to be able 
to claim that you can use it to achieve that result.”  
 
This statement shows the importance of understanding the required documentation process. This 
lack of knowledge can cause a great deal of rework, and this particular researcher needed to start 
a company to redo some of the development work in order to create the necessary 
documentation.   
 
Lack of Resources 
To overcome their minimal expertise on regulatory compliance, the Research Projects 
also needed human and financial resources.  University settings are helpful in research; however, 
they do not provide the resources a company does to further the product on the path to 
commercialization. To overcome this barrier, researchers with a marketable product may create a 
company. An interviewee explained the added that the money and expertise a company brings 
may be necessary for success. Hiring full-time experts that can be devoted to the project is 
beneficial. This researcher explained how they “started a company to commercialize it.  That 
company is taking it through the FDA.  That is expensive to do, and there is expertise that is 
required to do it.  The company has an FDA consultant who understands how to go about doing 
those filings with the FDA.”  Without specialized FDA experts at the university, this researcher 
pursued another way to gain advice and help.  
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Although starting a company seems like the best way to pursue commercialization and 
approval, it can be a challenging path with hefty expenses. A researcher explained that they felt 
there was no other way to bring their product to market other than partnering with a company or 
starting one. He explained that starting a company is “really expensive, and we don’t have the 
NIH funding to help you get through that process, but most academics do not have any 
experience with that.  It’s very different from the majority of what we do for our research and the 
way that we write proposals.  Usually, people would partner with companies.”  
Partnering with companies can be a mutually beneficial path as long as both parties have 
enough confidence in each other in order for the collaboration to work. Most companies will not 
risk resources for a product without a proven need or a high possibility of success. There is also 
no specified process for collaborating with a company and it can be challenging for a researcher 
that does not have experience building this type of relationship. Other researchers are lucky 
enough to have personal connections to information sources such as other universities, 
companies, or consultants. One researcher explained how they gathered information and where 
they got it from in the following quote.  
Well in our case, we did have some input and insight from people that have medical 
device experience in developing and working with regulatory agencies so people that 
have worked in industry for a while, so I would classify them as consultants. In some 
cases, one of the consultants was unpaid and a personal connection. Another case, the U 
of R actually has a translational research center you may know of. So they actually have 
staff that are there to help you with that.  So they are able to point us to some documents, 
but in the end we had to interpret them ourselves because they were not experts in exactly 
what we wanted to do. But it did give us some direction in where we wanted to go.” 
 
A large issue encountered by researchers is a lack of resources and funding. A lab usually 
employs or allows students to work in a lab for financial compensation or experience. Students in 
research labs looking to gain experience in their designated field usually perform the tedious 
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tasks of documentation and other clerical tasks for FDA approval. These tasks are often seen as 
busy work and not given the proper care or attention they should. Even with the research 
assistants able to do little work on documentation, it is nowhere near the necessary amount 
needed for FDA approval submissions. Lack of funds and resources leads to products not 
reaching their full potential or using an external company. The lack of funds for one project 
during COVID-19 halted their progress.  As explained by one person: “as our supplies dwindled, 
the financial security of the university came into play and so we weren't going to be able to 
purchase tens of thousands of dollars of material.” In this case, the lab's work ended due to the 
considerable lack of resources.  
 
Lack of Motivation  
Another barrier might be the researchers’ own motivation to commercialize the 
technology. Some researchers are not interested in commercializing the product on their own but 
are open to building a device with the potential for commercialization to be pursued by a 
company collaboration. These researchers aim to prove that the product is helpful and useful in 
the medical field; however, they are not interested in anything more. A researcher's main 
objective is to discover the technology, not sell or approve products. One creator at the university 
explained his feelings on discovery and innovation as, “when it comes to regulation, makers in 
general don't pay attention to it. Because they're not thinking about commercializing it, or they're 
not going to be using it on people. So the safety’s not safe there.”  One person indicated that the 
developer wants the product to fulfill its potential but is not interested in the process to get it 
further than a lab.  They said, “that’s one where we right now are trying to follow some of these 
ASTM standards to make sure whatever data we do collect would be meaningful to someone that 




A common consideration for owners of the Research Projects was how to be impacted the 
least by compliance and regulation, as rework and wasting time is not desirable. Three out of 
four device projects collaborated with companies that help to optimize the commercialization 
process. The interviewees mentioned changing their devices to avoid setbacks. Based on the 
expertise of collaborators and the possibility of changing the function of a device, work can be 
done to lessen the impact of regulation and compliance. Some interviewed also believed that the 
timing of their consideration of FDA regulations for regulation had an impact on the ultimate 
product design. In some instances, early compliance consideration can change the entire project. 
When talking to the interviewee of Project 1, he began describing the effect of the FDA 
regulations as, “It made us decide not to do a [certain product function].” He went on to say, “At 
the early stages of design, we made that decision so that it would relieve the burden on us to 
begin doing human subject testing.” With this change, the project would use a cheaper and 
quicker FDA approval pathway when the time comes to apply for FDA approval. 
Alternatively, sometimes a necessary design change may not happen because 
consideration for compliance did not occur until the project’s end. A product could miss 
compliance criteria or lack the necessary testing. Another interviewee said, “What that means is, 
if I produce the devices out of the university and we get all these great results from this study, 
which is a five-year study, I can’t actually use it to submit to the FDA.” It is important to note 
that it is not always the owner’s fault, but it points to the need for a better understanding of the 






As stated earlier, Sponsored Projects are run by students, not funded directly by RIT, and 
use RIT resources. This section will continue to look at the resources for compliance, barriers 
experienced by project owners, and the impact each had on the sponsored products.  
 
Information Resources 
Products 3, 4, 5, 6, and 7 were Sponsored Projects and relied on a student team-based 
approach to development. Within the teams, specific members were responsible for gathering the 
compliance information. 







Knowledge Customer Internet 
3 X X   X 
4   X  X 
5 X  X  X 
6     X 
7 X   X X 
 
For these projects, most of the information resources were found through internet 
searches. The product 3 team, working on Class I equipment, first used an internet search to 
acquire information and had difficulty finding the resources they needed on the internet.  They 
used what little resources they could find. Their precedence for FDA approval can help design 
new products; however, the student must understand the purpose. Other resources at RIT were 
also unhelpful.  Finally, they turned to another university they had a connection with. It took one 




A team member working on Product 3 recalled, “I talked to a professor that said RIT 
lacks at helping students with documentation, research, and knowing what to do. So I scheduled 
a meeting with our customer, who is a medical director at another college, and she got me into 
contact with the regulatory director at another university, and he gave guidance on the clearances 
we needed.” A team member for Product 4, a Class I equipment, did their own research.  He 
concluded that due to the nature of their product, no testing or FDA concerns were necessary. 
The team member drew the conclusion from online research but did not consult any expert or 
contact the FDA to corroborate this conclusion. Their lack of assurance from expert sources may 
be a risk when furthering the device for commercialization. 
 Product 5, a Class I device, used a single team member to do the FDA compliance 
research for the project. The search resulted in vague results. Their information was based 
mainly on design standards and predicate devices, which are used as a point of comparison for 
new medical devices seeking approval (“Predicate Device: Greenlight Guru,” n.d.). The team 
guide, a faculty member appointed to assist in any issues, was unsure how to help with the 
search. The team relied solely on the internet and still does not believe their results were 
thorough enough to be confident in receiving FDA approval. 
Product 7, a Class I or II device, relied heavily on internet research and predicate device 
standards. The standards for many predicate devices did not help the team, as their product 
design was to be completely different from previous products; their internet research resulted in 
generic results that needed interpretation. The team decided to follow some International 
Organization for Standardization (ISO) standards for the materials used in the product and then 
rely on mechanical testing for safety standards. 
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All of the students relied on the internet for information. As mentioned earlier, internet 
information, such as information on device class, can be interpreted in many ways and may set a 
project up with incorrect information. Students also looked to international design standards for 
their product because they needed indisputable and unquestionable sources. The incentive to 
commercialize may be lower for these products because uncertainty in the path to compliance 
makes it a riskier endeavor. Without expert consultation, no one could be sure the information 
the students gathered was 100% correct. Lastly, the personal knowledge the students used was 
more often intuition-based than experience-based. This is not promising for compliance 
standards and moving forward with FDA approval. The only student with an expert consultation 
used her personal connections for the information, which all students do not have access to.  
 
Primary Barriers Encountered 
 Lack of Knowledge 
For this group of products, there were several barriers mentioned by project owners. 
Some of these issues were caused by a lack of knowledge.  It was usually a student's first time 
navigating the FDA compliance information; therefore, the students were unsure how to proceed 
with much of the investigation. The students also must interpret all findings on the internet, and 
without previous knowledge, they may consider inaccurate or incomplete information to be true. 
For example, one of the students stated, “For regulatory information, I did most of the research. 
There were ISO standards I found, however, nobody told me whether I needed that. It was hard 
to find, so I put a lot of time into it. There were ASTM, ISO, and IEEE standards, and I found the 
device class and used it as a guideline knowing in the future it would be able to pass FDA 
approvals.” The student used information recognized for engineering practices; however, it is not 
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explicitly for medical devices. There is much that goes into the safety and efficacy of a project 
besides the mechanical properties. Based on the lack of information for the student, they used the 
best compliance suggestions available.  
As another example, until the final product design is near completion, it may be unknown 
whether the device can use an existing predicate and therefore be exempt from a pre-market 
approval process and qualified for a 501(k). This happened for Project 7. One student stated that, 
“We believed we could use a 501(k) device pathway so we put in much time learning about the 
process and understanding predicate devices. By the end of our design process, we found out that 
the device would need to go through a different process.” Without a knowledgeable consultant, 
the team’s assumption caused extra work and wasted time. This mistake could have been 
avoided with more understanding of the process. It is unclear whether the student prematurely 
chose a pathway and needed to change the product after initial designs or if the student 
misunderstood the FDA requirements. Either way, the student was confused about the process, 
and prematurely chose a pathway that caused unnecessary rework time and cost.  
With many companies having departments committed explicitly to stay up to date with 
FDA regulations, it is no surprise that students would have trouble navigating the changes in 
regulatory standards that frequently occur. With so much information and change, it is 
challenging for an inexperienced FDA regulation interpreter to stay up to date with everchanging 
FDA policies.  
  
Lack of Guidance 
At RIT, students typically research FDA pathways in classroom settings before creating 
any product prototypes to help with design requirements. Without experience and a full 
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understanding of the regulatory field, students can make incorrect choices for their product 
design. It is easy to decide an approval pathway before the product is finished; however, this 
ultimately may not be the best pathway. As seen previously in product 1, experts suggested 
changing the product slightly to avoid a more stringent pathway. However, the experience and 
knowledge used to make that decision are not available for all students. Even with specific 
faculty and guides, the lack of experts trained on FDA matters has an effect. A student explained, 
“Our guide was trying to understand the process with us and at times interpreted the information 
wrong.” 
 Some students used personal resources to further their product because they could not 
find the necessary help at RIT. The student could not locate staff knowledgeable enough on their 
needs and had trouble finding the internet information. When asked if the campus resource was 
helpful, the student replied, “No, they were not helpful.” When asked if they could use the 
established design standards as a means for knowing if they would pass FDA approval, the 
student replied, “I don't know if we would. I don't think this would need to go through the FDA, 
maybe a predicate device. It could also be a Class I. I think further iterations would be.” The 
design of this product did not change much throughout the development process. It can be 
assumed that the uncertainty stems from a lack of knowledge rather than any design changes. 
This answer shows a large amount of uncertainty in their work. Handing a product with that 
much uncertainty off to be commercialized can cause a bad reputation for the university.  
 
Impact 
 Most impacts of the resources and barriers were negative for Sponsored Projects. As 
noted previously, the students’ resources were not sufficient, and they often did not understand 
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compliance standards. Many students turned to international design standards for guidance, 
which had a small impact on their designs. Product 4 and 8 chose their product material based on 
design standards. The design standards helped guide the students but did not impact their design 
significantly.  
 The Sponsored Projects all waited considerably longer in the design process than the 
Research Projects to consider compliance, but not many students would know that.  It is 
concluded that a sooner consideration with expert experience and knowledge can help save time 
and money. With proper guidance and resources from the university, the product’s impact can be 
improved rather than minimized. The lack of resources kept the students uninformed on how 
specific product characteristics can alter the FDA pathways that they choose.  
 
Individual Project 
 As stated earlier, Individual Projects are recognized by RIT, not funded directly by RIT, 
and RIT is not a stakeholder of the project. 
 
Information Resources 
As shown in Table 5, the Individual Project did not rely on RIT help and used the 
internet, the FDA hotline, and international design standards. The outreach to the FDA proved to 
be subjective due to multiple responses with conflicting information. As mentioned earlier, one 
FDA worker said the device would be Class I, while the other said it would be Class II because it 
related to a deadly disease.  
Table 5: Resources used by the Individual Project for compliance and design requirements. 
Product Design Standards Expert Consult Personal Knowledge Customer Internet 




Product 10, an individual product founded at RIT, could fall under a Class I or II 
category. This product began during the beginning of the COVID-19 pandemic with a vision of 
improving an existing product rather than creating a new device. Navigating the approval process 
during the pandemic proved to be difficult for the team. They found that new exemptions and 
changes to speed approvals caused even more confusion. The interviewee explained how they 
“spent countless hours on the phone with them [the FDA] trying to figure out what classification 
our device is and received a different answer every time.  They weren’t able to give us the 
answers we needed.  So, in general, it has been a pretty difficult process, maneuvering the FDA.” 
The fast-paced nature of commercializing during a pandemic was not something the team could 
find resources on and at times felt lost in a sea of contradicting information.  
 
Primary Barriers Encountered 
 
Only one of the products within this case study is considered an individual product. 
While an RIT student is conducting it, it is not being funded or located on campus. The student 
has encountered many difficulties with finding the necessary information and funding. The 
student is self-employed, thus responsible for obtaining both. Their experience with finding 
approval information has not been comfortable, and they have gone as far as contacting the FDA 
directly. However, the information received from each consultant has slight irregularities and is 
subjective. To tackle funding, the student had to improvise and use the resources they already 
had for manufacturing. The student stated, “Basically, where we left off is that we did not have 
the necessary funds for a huge down payment for mass manufacturing, so we kind of made our 
own on the side, we printed them, we would rather have them injection molded, but we printed 
them cause that is what we can do.” The student knew that the cheaper way was not the best, but 





The resources and barriers of this project did not have a physical impact on the 
equipment.  However, it did impact the timeline of the project. The uncertainty about resources 
and difficulties communicating with the FDA caused a slower timeline for the project. In this 
case, time wasted meant money wasted, and it eventually slowed the project to a halt, missing a 













Chapter VI: Discussion and Conclusion 
 
Analysis of Findings 
 
  This study highlighted the difficulties faced by innovators at multiple levels at the 
Rochester Institute of Technology. The analysis shows the current resources and supports the 
projects have is insufficient in overcoming the barriers and issues they face. Lastly, compliance 
is daunting and may push researchers away from considering their device for the market. With 
proper help, the success rate could increase and limit the struggles faced by students and 
researchers. Luckily, some researchers could collaborate with companies, experts, and other 
helpful resources. On the other hand, students participating in innovation at RIT lacked 
knowledge and resources to acquire this knowledge advance, e missing out on potential success 
for their project and the Institute. These limitations slowed project progress, led to incorrect 
information, and hampered project success. A consistent theme in the interviews was how 
information about regulatory requirements for a specific product was difficult to come by.   
 
Figure 2: A comparison of project types and a pathway to their confidence in compliance. 
The first research question to be answered is, “What sources of information did the 
project have to learn about compliance standards for FDA regulations?” Across the ten devices, 
most researchers obtained their knowledge through entirely different sources, and not all of these 
sources were easy to use or reliable.  As shown in Figure 2, the primary information source for 
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Sponsored and Individual Projects was the internet, while Research Projects have access to 
company experts. Based on the information pulled from the interviews, it can be concluded that 
the quality of information depended on the source. The research showed that no projects could 
complete innovation to market processes using only RIT resources. Similarly, the lack of 
resources and funding for compliance and approval efforts was a central theme across the 
projects. The access to company collaboration and resources gave owners high confidence in 
compliance. Thus, there seems to be a strong correlation between the origin of the project and the 
strength of their resources. The Research Projects had external resources and experts while 
Sponsored, and Individual Projects used more internet and personal knowledge. This may be 
because support for Sponsored Projects tends to come from customers with small fixed budgets.   
Although it is clear that using external resources, such as those found in an established 
company, has advantages, these resources are not always easy to attain. The external connections 
used for the Research Projects are gained throughout the researcher’s experience, and typically 
not through RIT.  The experts used by the researchers are not advertised to the entire university 
body.  It is important to keep in mind, as stated in the literature review, there is a need for 
continued research and collaboration, even following the commercialization of technology. This 
type of continued support is a burden that universities cannot bear (Pober et al., 2001).  
As expected, all of the projects faced barriers related to regulatory compliance; however, 
the issues were different based on the type of project. The Individual and Sponsored Projects had 
issues that related to lack of knowledge and a lack of resources to attain this knowledge, which 
led to confusion, frustration and misinformation. On the other hand, while Research Projects had 
problems related to knowledge, such as FDA documentation requirements, and lack of university 
resources to acquire this knowledge, some projects were able to overcome this barrier through 
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external collaboration. It was clear from interviews that different resources available to the 
projects affected the type of issues they experienced.  
Lastly, perceptions of regulatory requirements did impact the product design choices. 
Multiple projects in the research and sponsored category changed their designs based on the 
resources and barriers. The Sponsored Projects had smaller tweaks based on design standards, 
while one Research Project changed a main function to avoid a more stringent FDA pathway.  
The cases highlight the importance of when a project starts considering FDA compliance.  
On one hand, the earlier you start considering this, the less rework you might require based on 
regulation and the fewer unexpected speedbumps. This is particularly important for regulatory 
requirements on product development documentation. I found, however, that some researchers 
are not interested in commercializing the product on their own and therefore do not consider 
FDA approval or the necessary documentation. For these products, it was only thought of after 
the product showed commercial promise. Thus, much of the testing and documentation needed 
rework. These researchers aim to prove that the product is helpful and useful in the medical field 
and it will be the partner company’s job to carry it to market.  
On the other hand, this points to a paradox when it comes to timing consideration. As 
seen with students, there can be issues with early consideration of regulation if the information is 
incorrect or is interpreted incorrectly. This has the potential to lead the project down a specific 
design path that might prove to be the wrong one. This points to the importance of access to 
expert consultation early in the innovation process.  
In conclusion, the investigative nature of the study found many instances of innovation at 
the Rochester Institute of Technology. However, none of the projects analyzed in this study 
could complete the commercialization process using RIT resources alone, and some faced 
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significant barriers. The origin of the project directly relates to the strength of the resources that 
are available for that project. Those products with little access to external expert’s struggle. The 
study concluded there was a significant gap in a university setting between FDA compliance, the 
commercialization process, and the resources and expertise needed to achieve it.  
Limitations 
 There are a number of limitations of this study. The limited amount of medical device 
innovation at RIT narrowed the sample size of the research. Only one person from each project 
team was interviewed, which may have restricted the experiences and information about each 
project. The lack of access to project details and only relying on interviews for project 
information may cause discrepancies in the data.  
The snowball sampling technique caused a nonrandom selection of each project 
(Johnson, 2014). Only ten projects were chosen, and they may have related experiences based on 
the sampling technique.  I also did not talk to administrators at RIT that might know of available 
projects that were not taken advantage of.  
Implications 
Implications for Research  
As noted in the literature review, there is a need to address regulatory concerns more 
specifically on the research that looks at commercialization of university research. This study 
shows that this is, indeed, a barrier to commercialization.  Future research can address the 
limitations of this study with large and less exploratory research on the topic.  Increasing the 
sample size, the number of individuals interviewed, and the number and type of universities 
investigated are a number of ways future research can build on this study.   For example, other 
universities, such as the University of Michigan (UM), have a different culture around medical 
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innovation. UM has an entire program to help innovators, which contributes to their supportive 
culture and big success. Conducting a comparative study would be very interesting. 
 
Implications for University Policy  
 
If RIT (and other universities) are genuinely interested in commercializing medical 
devices, they need to provide better support for the regulatory compliance aspect of medical 
device innovation. This support can take multiple forms. With some students forced to find 
experts at another university, an open channel with other universities would allow innovators to 
gain access to information not available at RIT.  
RIT currently runs a Personalized Healthcare Technology program that aims to “integrate 
interdisciplinary research” to solve medical problems (Personalized Healthcare Technology, 
n.d.). However, this program does not solve or mention the issues associated with regulation or 
compliance efforts, as analyzed in this thesis.  
Education and training for those involved in innovation could go a long way for the 
university. There is currently a lack of knowledge or where to look elsewhere for it. There are 
some researchers on campus with experience in compliance that could help students relying on 
personal knowledge and the internet. However, there are not enough people with the amount of 
knowledge needed. Specifically, for students that do not have access to external resources or 
companies, a full-time regulatory expert would be useful. The expert could also aid faculty and, 
thus, would significantly decrease rework times and facilitate innovation efforts. 
Alternatively, the university could help facilitate external networks with regulatory 
experts. Teaming up with a company or expert as soon as the product shows promise would 
relieve some barriers and extra rework. This type of network could also help medical device 
innovators at the university to share their experience with each other on topics such as 
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documentation, testing, and other difficulties. With stronger documentation of observations 
regarding the regulatory and compliance process, a network can educate other innovators in the 
same scenario.   Previously, I mentioned how the Wallace H. Coulter Foundation at the 
University of Michigan was created to give students and staff the help needed to commercialize. 
This could be a model for other universities, including RIT, could use to build structures and 
change the culture to support collaboration between the university faculty and professionals in 
the medical field (Pienta, 2010). This would require extra support at the university level.  
Implications for FDA Policy 
FDA policy can do more to explicitly address the barriers for university innovators, such 
as lack of knowledge, lack of guidance, and lack of motivation. FDA policy has proven to be 
difficult to navigate for many I interviewed. From the novice’s perspective, the FDA does not 
have clear-cut instructions on how to achieve compliance works. To decrease the knowledge 
barrier, more accessible resources need to be available for researchers and students. The current 
information can be seen as confusing, non-specific, and difficult to find. The FDA could easily 
understand quick fact sheets or a more comprehensive requirement list for innovators to 
reference. The information for innovation is not placed together on the website. The interviewees 
explained how information was hard to find or confusing to understand; hence, why multiple 
project owners began companies with paid experts.  
To address the lack of information and guidance, more grants could be created by the 
FDA to have specialists visit universities. Another idea is to offer guest lectures to universities 
by compliance specialists. Often, students and researchers are wary of reaching out to the FDA 
first. To address this problem, the FDA could develop a program to reach out about compliance 
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